Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

186 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
Nissen SE, Wolski K. Nissen SE, et al. Among authors: wolski k. N Engl J Med. 2007 Jun 14;356(24):2457-71. doi: 10.1056/NEJMoa072761. Epub 2007 May 21. N Engl J Med. 2007. PMID: 17517853
Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT.
Cho L, Bhatt DL, Wolski K, Lincoff M, Topol EJ, Moliterno DJ. Cho L, et al. Among authors: wolski k. Am Heart J. 2001 Apr;141(4):599-602. doi: 10.1067/mhj.2001.113573. Am Heart J. 2001. PMID: 11275926
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowski Z, Betriu A, Booth JE, Wolski K, Waller M, Topol EJ; Global Use of Strategies To Open Coronary Arteries Investigators (GUSTO). Lincoff AM, et al. Among authors: wolski k. JAMA. 2002 Nov 6;288(17):2130-5. doi: 10.1001/jama.288.17.2130. JAMA. 2002. PMID: 12413372 Clinical Trial.
Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices.
Exaire JE, Dauerman HL, Topol EJ, Blankenship JC, Wolski K, Raymond RE, Cohen EA, Moliterno DJ; TARGET Investigators. Exaire JE, et al. Among authors: wolski k. Am Heart J. 2004 Jan;147(1):31-4. doi: 10.1016/j.ahj.2003.07.019. Am Heart J. 2004. PMID: 14691415 Clinical Trial.
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Brener SJ, et al. Circulation. 2004 Aug 24;110(8):994-8. doi: 10.1161/01.CIR.0000139868.53594.24. Epub 2004 Aug 9. Circulation. 2004. PMID: 15302778
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J, Lincoff AM, DeSmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K, Topol EJ; REPLACE-2 Investigators. Saw J, et al. Among authors: wolski k. J Am Coll Cardiol. 2004 Sep 15;44(6):1194-9. doi: 10.1016/j.jacc.2004.06.049. J Am Coll Cardiol. 2004. PMID: 15364319 Clinical Trial.
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.
Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleiman N, Feit F, Wolski K, Bittl JA, Wilcox R, Topol EJ, Lincoff AM. Gurm HS, et al. Among authors: wolski k. J Am Coll Cardiol. 2005 Jun 21;45(12):1932-8. doi: 10.1016/j.jacc.2005.02.074. J Am Coll Cardiol. 2005. PMID: 15963389 Clinical Trial.
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
Nissen SE, Wolski K, Topol EJ. Nissen SE, et al. Among authors: wolski k. JAMA. 2005 Nov 23;294(20):2581-6. doi: 10.1001/jama.294.20.joc50147. Epub 2005 Oct 20. JAMA. 2005. PMID: 16239637
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Nissen SE, et al. Among authors: wolski k. JAMA. 2006 Apr 5;295(13):1556-65. doi: 10.1001/jama.295.13.jpc60002. Epub 2006 Mar 13. JAMA. 2006. PMID: 16533939 Clinical Trial.
Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention.
Robertson JO, Lincoff AM, Wolski K, Topol EJ. Robertson JO, et al. Among authors: wolski k. Am J Cardiol. 2006 Jun 15;97(12):1679-84. doi: 10.1016/j.amjcard.2005.12.066. Epub 2006 Apr 21. Am J Cardiol. 2006. PMID: 16765113 Clinical Trial.
186 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback